难治及复发尤文肉瘤大剂量化疗后的生存分析
该研究回顾性分析了伦敦肉瘤服务中心22年间收治的196例难治或复发尤文肉瘤(RRES)患者,其中64例接受大剂量治疗(HDT),98例接受标准非HDT化疗,34例未接受全身治疗。HDT患者中位总生存为76个月(95%CI 34.8-117.2),非HDT患者为10.5个月(95%CI 8.9-12.1)。研究还建立了包含4个预后因素的评分系统,评分越高复发后生存越差。
要点
- RRES患者中,HDT组中位总生存76个月(95%CI 34.8-117.2),非HDT组10.5个月(95%CI 8.9-12.1)。
- HDT组2年和5年复发后生存分别为67.9%(SE 5.9)和52.7%(SE 6.5),非HDT组为20.5%(SE 4.2)和2%(SE 1.5)。
- 多因素分析中4个预后因素各计1分,形成良好(0分)、中等(1-2分)和不良(3-4分)预后组,评分增加与复发后生存降低显著相关。
核心结论
- 在RRES患者中,HDT与非HDT化疗相比与更优的生存结局相关。
- RRES患者可根据本研究开发的预测性预后指数进行风险分层,即使在预后评分不良的患者中也可观察到HDT的潜在获益。
研究设计与样本
- 回顾性研究,纳入伦敦肉瘤服务中心(LSS)22年间收治的196例RRES患者。
- 64例接受HDT,98例接受标准非HDT化疗,34例未接受全身治疗。
- RRES时中位年龄20岁,74%的患者在24个月内进展或复发。
主要发现
- HDT患者中位总生存为76个月(95%CI 34.8-117.2),非HDT患者为10.5个月(95%CI 8.9-12.1)。
- HDT患者2年和5年复发后生存分别为67.9%(SE 5.9)和52.7%(SE 6.5),非HDT患者分别为20.5%(SE 4.2)和2%(SE 1.5)。
- 多因素分析中4个预后因素各计1分,形成良好(0分)、中等(1-2分)和不良(3-4分)预后组,评分增加与复发后生存降低显著相关。
关键数值与推荐
- 预后评分:4个多因素分析显著的预后因素各计1分,总分0分为良好,1-2分为中等,3-4分为不良。
- 评分增加与复发后生存降低显著相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: outcome of primary refractory or recurrent Ewing sarcoma (RRES) is poor and the role of high-dose therapy (HDT) remains uncertain. We retrospectively reviewed all patients treated for RRES in the London Sarcoma Service (LSS) over a 22-year period with the aim of adding to the current literature and developing a prognostic risk score to aid clinical decision-making. METHODS AND RESULTS: One hundred and ninety-six patients were included; 64 patients received HDT, 98 standard non-HDT chemotherapy and 34 no systemic therapy. At RRES, median age was 20 years and seventy-four per cent of patients had progressed or relapsed within 24 months. Median overall survival for HDT and non-HDT patients was 76 months (95% CI 34.8-117.2) and 10.5 months (95% CI 8.9-12.1), respectively. Two and five-year post-relapse survival (PRS) for HDT patients was 67.9% (SE 5.9) and 52.7% (SE 6.5), and for non-HDT patients, 20.5% (SE 4.2) and 2% (SE 1.5). Four prognostic factors significant on multivariate analysis were assigned a score of one point each, creating good (score 0), intermediate (score 1-2) and poor (score 3-4) prognosis groups. The increased score was significantly associated with reduced PRS. CONCLUSION: Our study demonstrates that in RRES, HDT is associated with superior outcomes compared with non-HDT chemotherapy. RRES patients can be risk-stratified according to a predictive prognostic index we have developed, with the potential benefit of HDT observed even in patients with poor prognostic scores.
引用
- Windsor R, Hamilton A, McTiernan A, et al. Survival after high-dose chemotherapy for refractory and recurrent Ewing sarcoma. Eur J Cancer. 2022. PMID: 35635934. doi:10.1016/j.ejca.2022.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。